ReviewFrontiers in physiology2026
PANoptosis and mitochondrial regulatory mechanisms in cerebral ischemia-reperfusion injury.
Review in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral ischemia-reperfusion injury remains a leading cause of mortality and disability despite advances in reperfusion therapy. Traditional research has focused on individual cell death pathways, yet pharmacological blockade of single pathways provides only partial neuroprotection, suggesting that dying cells engage multiple death routes simultaneously. This review examines whether PANoptosis, an inflammatory cell death modality characterized by concurrent activation of apoptotic, necroptotic, and pyroptotic pathways, occurs in cerebral ischemia-reperfusion injury. The analysis demonstrates that mitochondrial dysfunction serves as the central convergence point orchestrating multi-pathway death activation across distinct temporal phases. Ischemia creates metabolic crisis that primes mitochondria without triggering irreversible commitment. Reperfusion causes explosive mitochondrial collapse through oxidative stress, releasing danger signals that simultaneously engage multiple death pathways. Impaired mitochondrial quality control then sustains inflammatory amplification over extended periods. Multiple lines of evidence support this framework, including concurrent rather than sequential appearance of pathway markers, mixed morphological features within individual cells, pathway redundancy demonstrated by incomplete single-target protection, and mechanistic convergence at the mitochondrial level. Cellular responses vary among neurons, astrocytes, microglia, and endothelial cells but share the common feature of coordinated multi-pathway activation. This integrated understanding explains why single-pathway therapeutic approaches have failed clinically and suggests that effective neuroprotection requires targeting upstream mitochondrial dysfunction or addressing pathway redundancy through multi-target interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.